5HJ0 Stock Chart & Stats
€0.27
-€0.06(-1.83%)
At close: 4:00 PM EST
€0.27
-€0.06(-1.83%)
Day’s Range― - ―
52-Week Range€0.26 - €4.48
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€6.48M
Enterprise Value-€1.83M
Total Cash (Recent Filing)€24.93M
Total Debt (Recent Filing)€603.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1147.01
Shares Outstanding667,669
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-29.84
Revenue Forecast (FY)€5.97M
Bulls Say, Bears Say
Bulls Say
FDA IDE Approval For TAVVEIDE clearance creates a clear regulatory pathway to generate pivotal clinical data and potentially support a future FDA post-marketing approval. This materially derisks development timelines, enables U.S. site activation and investigator engagement, and enhances long-term commercial optionality.
Cash Runway Into Q3 2027A reported cash balance funding operations into Q3 2027 provides near-term financing stability to execute enrollment and initial pivotal stages without immediate capital raises. This supports trial continuity and reduces short-term dilution risk while key regulatory milestones are pursued.
Very Low Reported DebtMinimal leverage preserves financial flexibility: low interest burden and borrowing constraints let management prioritize trial execution and potential partnerships. Relative debt conservatism is a durable balance-sheet strength among clinical-stage device peers.
Bears Say
Pre-revenue With Sustained LossesNo commercial revenue means the business model has not yet been validated in market; persistent multi-year losses highlight that profitability depends entirely on successful trial outcomes, regulatory approval and commercialization—each carrying execution and timing risk.
Consistent Negative Operating Cash FlowMaterial cash burn is structural while the company remains in clinical development. Continued negative operating and free cash flow will necessitate further external financing for later-stage trials or commercialization, raising dilution risk and constraining strategic optionality over the medium term.
Eroding Equity And Very Negative ROEDeclining equity and sharply negative returns signal ongoing shareholder value erosion from operations. Over months this weakens the balance sheet cushion, limits leverage capacity for growth, and increases sensitivity to trial setbacks or capital market disruptions.
enVVeno Medical News
5HJ0 FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was €0.26 and its highest was €4.48 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is €6.48M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is Jul 30, 2026 which is in 25 days.
How were enVVeno Medical’s earnings last quarter?
enVVeno Medical released its earnings results on May 07, 2026. The company reported -€5.143 earnings per share for the quarter, missing the consensus estimate of N/A by -€5.143.
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 667,669 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
enVVeno Medical reported an EPS of -€5.143 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in DE:5HJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Technical Analysis
Options Prices
Currently, No data available
---